COMPASS THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
COMPASS THERAPEUTICS, INC. (CMPX) reported Increase (Decrease) in Accounts Payable of $1.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.00M, a 96.46% increase year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$679.00K.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.51M, a 217.15% decline year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $500.00K.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$664.00K.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$1.84M, a 360.03% decline from fiscal 2023.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $708.00K, a 71.85% decline from fiscal 2022.
- COMPASS THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $2.52M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.32M 10-Q · filed 2026-08-06 | -$189.00K derived: sum of 3 quarters · filed 2026-08-06 | $311.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$679.00K 10-Q · filed 2026-05-05 | -$2.19M derived: sum of 2 quarters · filed 2026-05-05 | -$1.69M derived: sum of 3 quarters · filed 2026-05-05 | -$671.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.01M derived: sum of 2 quarters · filed 2026-03-05 | $8.00K derived: sum of 3 quarters · filed 2026-08-06 | -$664.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.52M derived: sum of 2 quarters · filed 2026-08-06 | $846.00K 10-Q · filed 2025-11-05 | $2.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $346.00K 10-Q · filed 2026-08-06 | $1.64M derived: sum of 3 quarters · filed 2026-08-06 | $1.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$672.00K 10-Q · filed 2026-05-05 | $617.00K derived: sum of 2 quarters · filed 2026-05-05 | $385.00K derived: sum of 3 quarters · filed 2026-05-05 | $723.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.06M derived: sum of 2 quarters · filed 2026-03-05 | $1.40M derived: sum of 3 quarters · filed 2026-03-05 | -$1.84M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$232.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $106.00K derived: sum of 2 quarters · filed 2025-11-05 | -$3.13M 10-Q · filed 2025-11-05 | -$1.35M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $338.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$2.90M 10-Q · filed 2025-08-11 | -$1.11M derived: sum of 3 quarters · filed 2025-08-11 | $468.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$3.24M 10-Q · filed 2025-05-08 | -$1.45M derived: sum of 2 quarters · filed 2025-05-08 | $130.00K derived: sum of 3 quarters · filed 2025-05-08 | -$271.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.37M derived: sum of 2 quarters · filed 2025-02-27 | $2.96M derived: sum of 3 quarters · filed 2025-02-27 | $708.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.18M derived: sum of 2 quarters · filed 2024-11-12 | -$1.08M 10-Q · filed 2024-11-12 | -$455.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$2.66M 10-Q · filed 2024-08-12 | -$2.04M derived: sum of 3 quarters · filed 2024-08-12 | -$5.73M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$2.26M 10-Q · filed 2024-05-13 | -$1.64M derived: sum of 2 quarters · filed 2024-05-13 | -$5.33M derived: sum of 3 quarters · filed 2024-05-13 | $869.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$3.07M derived: sum of 2 quarters · filed 2024-03-21 | $3.13M derived: sum of 3 quarters · filed 2024-03-21 | $2.52M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.50M derived: sum of 2 quarters · filed 2023-11-09 | $1.89M 10-Q · filed 2023-11-09 | $1.89M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.59M 10-Q · filed 2023-08-03 | $5.59M derived: sum of 3 quarters · filed 2023-08-03 | $5.90M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$611.00K 10-Q · filed 2023-05-04 | -$612.00K derived: sum of 2 quarters · filed 2023-05-04 | -$303.00K derived: sum of 3 quarters · filed 2023-05-04 | -$805.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $308.00K derived: sum of 2 quarters · filed 2023-03-15 | -$194.00K derived: sum of 3 quarters · filed 2023-03-15 | -$194.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$193.00K derived: sum of 2 quarters · filed 2022-11-09 | -$193.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$502.00K 10-Q · filed 2021-08-16 | ||
| 2021-06-20 | -$502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$502.00K 10-Q · filed 2022-08-01 | -$264.00K derived: sum of 3 quarters · filed 2022-08-01 | -$1.02M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $238.00K derived: sum of 2 quarters · filed 2022-05-09 | -$520.00K derived: sum of 3 quarters · filed 2022-05-09 | $717.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$520.00K derived: sum of 2 quarters · filed 2022-03-18 | $717.00K derived: sum of 3 quarters · filed 2022-03-18 | $432.00K 10-K · filed 2022-03-18 |
| 2020-09-30 | -$758.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $479.00K derived: sum of 2 quarters · filed 2021-11-12 | $194.00K 10-Q · filed 2021-11-12 | $196.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $952.00K 10-Q · filed 2021-08-16 | $954.00K derived: sum of 3 quarters · filed 2021-08-16 | $1.13M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$285.00K 10-Q · filed 2021-04-30 | -$283.00K derived: sum of 2 quarters · filed 2021-04-30 | -$106.00K derived: sum of 3 quarters · filed 2021-04-30 | |
| 2019-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $179.00K derived: sum of 2 quarters · filed 2021-03-05 | -$1.10M 10-K · filed 2021-03-05 | |
| 2019-09-30 | $177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$1.10M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | -$1.28M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |